報價延遲最少15分鐘:2026/03/28 17:37 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.34 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.02/-0.12
|
|
企業價值
420.60M
|
| 資產負債 |
|
每股賬面淨值
0.12
|
| 現金流量 |
|
現金流量率
0.19
|
| 損益表 |
|
收益
236.20M
|
|
每股收益
0.75
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
